Advertisement
Advertisement
COGT
Cogent Biosciences, Inc. Common Stock
31.02
USDSponsored
-0.94
-2.94%
Oct 30, 15:59 UTC -4
Closed
After-Market
31.32
+0.30
+0.98%
Cogent Biosciences, Inc. Common Stock (COGT) Earnings
COGT Earnings Reports
Positive Surprise Ratio
COGT beat 15 of 34 last estimates.
44%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.57
Implied change from Q2 26 (Revenue/ EPS)
--
/+9.62%
Implied change from Q3 25 (Revenue/ EPS)
--
/+14.00%
Cogent Biosciences, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, COGT reported earnings of -0.52 USD per share (EPS) for Q2 26, beating the estimate of -0.58 USD, resulting in a 10.45% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.03% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.57 USD, with revenue projected to reach -- USD, implying an increase of 9.62% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
AstraZeneca PLC
Report Date
Oct 30, 2026 For Q3 26
Estimate
$2.66
Actual
$2.79
Surprise
+4.56%
Gilead Sciences Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.24
Actual
$2.54
Surprise
+13.66%
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.18%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
FAQ
What were Cogent Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Cogent Biosciences, Inc. Common Stock reported EPS of -$0.52, beating estimates by 10.45%, and revenue of $0.00, 0% as expectations.
How did the market react to Cogent Biosciences, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -2.03%, changed from $42.39 before the earnings release to $41.53 the day after.
When is Cogent Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Cogent Biosciences, Inc. Common Stock's next earnings report?
Based on 9
analysts, Cogent Biosciences, Inc. Common Stock is expected to report EPS of -$0.57 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.